Dongin (Donoven) Kim, Ph.D.
Assistant Professor
Pharmaceutical Sciences
Phone (405) 271-6593 x 47473
Office College of Pharmacy, CPB 317
Email dongin-kim@ouhsc.edu
Publications & Presentations
- 1. Kim D. SORL1-Mediated EGFR and FGFR4 Regulation Enhances Chemoresistance in Ovarian Cancer . Cancers. 2025; 17
2. Kim D. Exosomes in diagnostic and therapeutic applications of ovarian cancer. J. Ovarian Res.. 2024; 17
3. Kim D. Mature microRNA-binding protein QKI suppresses extracellular microRNA let-7b release. J Cell Sci. 2024; 137
4. Kim D. Minimal information for studies of extracellular vesicles (MISEV 2023): From basic to advanced approaches . Journal of Extracellular Vesicles . 2024; 13 : e12404
5. Kim D. Nanoparticles loaded with IL-2 and TGF-b promote transplantation tolerance to alloantigen. Front. Immunol.. 2024; 15
Grants
- 1. Extracellular Vesicle-Based Intraocular Therapy Combined with Active Targeting of Ocular Neovascularization. NEI. Start Date: 2024. End Date: 2029.
2. MiPEP133, a New Tumor Suppressor for Ovarian Cancer. American Cancer Society. Start Date: 2024. End Date: 2027.
3. Extracellular Vesicle Therapy for Diabetic Retinopathy. NEI. Start Date: 2023. End Date: 2024.
4. Lymphatics and lymphangiogenesis in kidney function and inflammation. NIH. Start Date: 2019. End Date: 2024.
5. Extracellular Vesicle Therapy for Diabetic Retinopathy. NEI. Start Date: 2023. End Date: 2024.
Awards and Honors
no results
Education
- 1. Degree: Ph D. University of Utah. Date: 2009.
2. Degree: MS. University of Florida. Date: 2002.
3. Degree: BS. Ajou University. Date: 1999.
Administrative Assignments
no results